Molecular Partners Bilan de santé

Santé financière contrôle des critères 6/6

Molecular Partners possède un total de capitaux propres de CHF138.8M et une dette totale de CHF0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont CHF154.2M et de CHF15.4M.

Informations clés

Ratio d'endettement

CHF 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CHF 143.62m
Fonds propres	CHF 138.78m
Total du passif	CHF 15.43m
Total des actifs	CHF 154.21m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MLLC.F ( CHF149.5M ) dépassent ses passifs à court terme ( CHF10.4M ).

Passif à long terme: Les actifs à court terme de MLLC.F ( CHF149.5M ) dépassent ses passifs à long terme ( CHF5.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: MLLC.F est sans dette.

Réduire la dette: MLLC.F n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: MLLC.F dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: MLLC.F dispose d'une marge de trésorerie suffisante pour 1.9 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 1.7 % chaque année.

Molecular Partners Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for ensovibep for the Treatment of COVID-19

Molecular Partners AG to Report Fiscal Year 2020 Results on Feb 26, 2021

Novartis AG (SWX:NOVN) acquired 6% stake in Molecular Partners AG (SWX:MOLN) for CHF 30 million.

Novartis Announces Collaboration with Molecular Partners AG to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19

Molecular Partners AG to Report Q1, 2021 Results on May 12, 2021

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of CHF 80.157291 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines